RS 8359

04/01/1994 - "Effects of repeated administration of RS-8359, (+-)-4-(4-cyanoanilino)-7-hydroxycyclopenta(3,2-e)pyrimidin e, (30 mg/kg x 2/day, p.o., 4 days) were examined at 3 days postischemia following 20 min of ischemia. "
04/01/1994 - "Effects of RS-8359 on reduced local cerebral glucose utilization in the rat subjected to transient forebrain ischemia."
12/01/1990 - "RS-8359 pretreatment (30 mg/kg, p.o.) at an hour prior to ischemia elevated the levels of NE in the cortex and hippocampus during ischemia and inhibited the increases in DOPAC and HVA levels and the decrease in 3MT levels at 30 min after reperfusion. "
12/01/1990 - "Changes in monoamine levels during and after ischemia and effects of RS-8359, a type A monoamine oxidase (MAO-A) inhibitor, were studied in the cerebral cortex, hippocampus, and striatum of rats killed by microwave irradiation. "
05/27/1991 - "Pretreatment with type A monoamine oxidase (MAO-A) inhibitors, clorgyline and RS-8359 ((+)-4-(4-cyanoanilino)-7-hydroxycyclopenta (3,2-e) pyrimidine) decreased significantly the number of necrotic neurons and inhibited changes in the dopamine metabolite contents during and after transient ischemia. "

09/01/1997 - "Moreover, the data on auditory-evoked potentials suggest that RS-8359 may improve cognitive performance, which is often impaired in major depressive disorders. "

03/01/1995 - "TL, TF and STL decreased in rats receiving brain ischemia, and we found that after treatment with RS-8359, TL and TF increased, but no effect was observed on STL. "